INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of PepGen Inc. (PEPG) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

Core Points - A shareholder class action lawsuit has been filed against PepGen Inc. alleging that the company made materially false and misleading statements regarding its business and operations [1] - The lawsuit specifically claims that PGN-EDO51 was less effective and safe than previously represented, and that the CONNECT2 study was inadequate for FDA approval [1] - As a result of these allegations, it is suggested that PepGen may halt the CONNECT2 study, leading to overstated clinical, regulatory, and commercial prospects for PGN-EDO51 [1] Legal Information - Shareholders who purchased PepGen shares between March 7, 2024, and March 3, 2025, and suffered significant losses are encouraged to discuss their legal rights [2] - The deadline to request to be appointed as lead plaintiff in the case is August 8, 2025 [3] - Holzer & Holzer, LLC is representing shareholders in this litigation and has a history of recovering significant amounts for investors affected by corporate misconduct [3]